This Biotech Has So Many Reasons to Be Liked
Motley Fool
With promising mid-stage results, the drug is expected to do well in phase 3 evaluation for pancreatic cancer.
Positive phase 3 results will open the door to the lucrative pancreatic cancer market, on top of the myelofibrosis market that is expected to …
READ ALL AT
http://www.fool.com/investing/general/2013/09/05/this-biotech-has-so-many-reasons-to-be-liked.aspx
